A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
A study for patients with moderate to severe Ulcerative Colitis using study drug ustekinumab
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAQ1262
U.S. Govt. ID: NCT02407236
Contact: Garrett Lawlor: 212-305-1021 / gl2501@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to see if ustekinumab is useful for treating patients with moderately to severely active ulcerative colitis. The safety of ustekinumab will also be studied.
This study is closed
Garrett Lawlor, MD
Do You Qualify?
Are you currently experiencing moderate to severe active Ulcerative Colitis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Garrett Lawlor